Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial | Zendy

Maria-Pilar Barretina-Ginesta | Zendy; Bradley J. Monk | Zendy; Sileny Han | Zendy; Bhavana Pothuri | Zendy; Annika Auranen | Zendy; Dana M. Chase | Zendy; Domenica Lorusso | Zendy; Charles Anderson | Zendy; Sophie AbadieLacourtoisie | Zendy; Noelle Cloven | Zendy; Elena Ioana Braicu | Zendy; Am Amit | Zendy; Andrés Redondo | Zendy; Ruchit Shah | Zendy; Nehemiah Kebede | Zendy; Carol Hawkes | Zendy; Divya Gupta | Zendy; Tatia Woodward | Zendy; David M. O’Malley | Zendy; Antonio GonzálezMartín | Zendy

Open Access

Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial

Author(s) -

Maria-Pilar Barretina-Ginesta,

Bradley J. Monk,

Sileny Han,

Bhavana Pothuri,

Annika Auranen,

Dana M. Chase,

Domenica Lorusso,

Charles Anderson,

Sophie AbadieLacourtoisie,

Noelle Cloven,

Elena Ioana Braicu,

Am Amit,

Andrés Redondo,

Ruchit Shah,

Nehemiah Kebede,

Carol Hawkes,

Divya Gupta,

Tatia Woodward,

David M. O’Malley,

Antonio GonzálezMartín

Publication year - 2022

Publication title -

therapeutic advances in medical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.272

H-Index - 49

eISSN - 1758-8359

pISSN - 1758-8340

DOI - 10.1177/17588359221126149

Subject(s) - medicine , placebo , progression free survival , nausea , quality of life (healthcare) , adverse effect , ovarian cancer , randomized controlled trial , oncology , surgery , chemotherapy , cancer , pathology , alternative medicine , nursing

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research